Clinical Trials Logo

Nervous System Neoplasms clinical trials

View clinical trials related to Nervous System Neoplasms.

Filter by:

NCT ID: NCT00045721 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Start date: March 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy placed into the surrounding tissue after surgery to remove the tumor may kill any remaining tumor cells. O(6)-benzylguanine may increase the effectiveness of carmustine by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the safety of combining O(6)-benzylguanine with carmustine implants in treating children who have recurrent malignant glioma.

NCT ID: NCT00045474 Completed - Clinical trials for Brain and Central Nervous System Tumors

Brachytherapy in Treating Patients With Recurrent Malignant Glioma

Start date: October 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Brachytherapy uses radioactive material to kill cancer cells remaining after surgery. PURPOSE: Phase I trial to study the effectiveness of brachytherapy in treating patients who have recurrent malignant glioma.

NCT ID: NCT00040911 Completed - Lymphoma Clinical Trials

Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma

Start date: April 2005
Phase: N/A
Study type: Interventional

RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in treating delayed nausea and vomiting in patients who are receiving chemotherapy for newly diagnosed childhood sarcoma, neuroblastoma, nasopharyngeal cancer, germ cell tumors, or Hodgkin lymphoma.

NCT ID: NCT00039572 Completed - Metastatic Cancer Clinical Trials

Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain

Start date: May 2002
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who have glioblastoma multiforme or melanoma metastatic to the brain.

NCT ID: NCT00039468 Completed - Clinical trials for Brain and Central Nervous System Tumors

Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy

Start date: March 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Thalidomide may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with irinotecan may kill any tumor cells remaining after radiation therapy. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide with irinotecan in treating patients who have glioblastoma multiforme that has been treated with radiation therapy.

NCT ID: NCT00039364 Completed - Clinical trials for Brain and Central Nervous System Tumors

Imatinib Mesylate in Treating Patients With Gliomas

Start date: March 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have gliomas.

NCT ID: NCT00036972 Completed - Clinical trials for Brain and Central Nervous System Tumors

Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma

Start date: November 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma. PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy before and after surgery in treating patients who have recurrent malignant glioma.

NCT ID: NCT00036959 Completed - Ovarian Cancer Clinical Trials

ABT-751 in Treating Young Patients With Refractory Solid Tumors

Start date: March 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors.

NCT ID: NCT00036894 Completed - Clinical trials for Brain and Central Nervous System Tumors

CC-5013 in Treating Patients With Recurrent Glioma

Start date: March 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.

NCT ID: NCT00036660 Completed - Clinical trials for Brain and Central Nervous System Tumors

SarCNU in Treating Patients With Recurrent Malignant Glioma

Start date: January 10, 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of sarCNU in treating patients who have recurrent malignant glioma.